期刊文献+

普伐他汀抑制重组人CD40配体诱导的U937诱导型细胞环氧合酶的表达

Pravastatin inhibits cyclooxygenase-2 expression induced by rhCD40L in cultured U937 cells
下载PDF
导出
摘要 目的 探讨重组人CD40 配体(rhCD40L)对培养的人单核细胞(U937)表达诱导型环氧合酶(COX 2)的作用和普伐他汀对其的影响。方法 体外培养U937 细胞,分别以浓度为0. 05、0. 10、0. 20、0.40μg/ml的rhCD40L刺激24 h;以0. 40μg/ml的rhCD40L 分别刺激3、6、12、24 h。再将0. 40μg/ml 的rhCD40L与终浓度分别为1×10-2、1×10-3、1×10-4 mmol/L的普伐他汀共同刺激24 h。采用逆转录聚合酶链反应(RT PCR)检测COX 2 mRNA的表达。结果 0.4μg/ml的rhCD40L刺激后3 h,可诱导COX 2 mRNA表达,随着rhCD40L浓度和作用时间增加,COX 2 mRNA表达明显增加(P<0.01),呈时效和量效的关系。0.4μg/ml的rhCD40L与普伐他汀共同刺激24 h后,COX 2 的表达明显被抑制。结论 rhCD40L可以时间和浓度依赖的方式诱导COX 2的表达,普伐他汀可抑制此作用。 Objective To evaluate the cyclooxygenase-2(COX-2) expression induced by rhCD40L in cultured U937 cell and the possible inhibition by pravastatin. Methods The U937 cells were cultured, co-incubated with rhCD40L in certain dosage and duration with or without pravastatin. The COX-2 expressions induced by rhCD40L were detected by RT-PCR. Results rhCD40L increased the expression of COX-2 mRNA in a time- and dose-dependent manner (P< 0.01). Pravastatin was founed to inhibit the expression of COX-2 mRNA induced by rhCD40L in a dose-dependent manner (P< 0.01). Conclusion rhCD40L can induce cyclooxygenase-2 expression in U937 cells with dose and time-dependent manners, and pravastatin can inhibit this enhanced expression.
出处 《上海医学》 CAS CSCD 北大核心 2005年第4期278-280,共3页 Shanghai Medical Journal
  • 相关文献

参考文献11

  • 1Linton MF, Fazio S. Cyclooxygenase-2 and atherosclerosis.Curr Opin Lipidol, 2002,13: 497-504.
  • 2Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology,physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol, 1999, 128: 1121-1132.
  • 3Massy ZA, Swan SK. Cyclooxygenase-2 and atherosclerosis,friend or foe? Nephrol Dial Transplant, 2001, 16: 2286-2289.
  • 4Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.Circulation, 1999,100: 614-620.
  • 5Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med,2002,12 : 27-32.
  • 6Lutgens E, Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med, 1999,5:1313-1316.
  • 7Schonbeck U, Libby P. CD40 signaling and plaque instability.Circ Res ,2001,89 : 1092-1103.
  • 8Mach F, Schonbeck U, Bonnefoy JY, et al, Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase,stromelysin, and tissue factor. Circulation,1997,96 : 396-399.
  • 9Zhang Y, Cao H J, Graf B, et al. CD40 engagement up-regulares cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J Immunol, 19980 1601053-1057.
  • 10Dongari-Bagtzoglou AI, Thienel U, Yellin MJ. CD40 ligation triggers COX-2 expression in endothelial cells: evidence that CD40-mediated IL-6 synthesis is COX-2-dependent. Inflamm Res, 2003,52 : 18-25.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部